PD-L1 and PIK3CA testing market seen reaching $3.4 billion by 2030

The global market for PD-L1 and PIK3CA testing is projected to grow from $1.93 billion in 2026 to $3.4 billion by 2030, as cancer cases rise and precision oncology adoption expands. North America led the market in 2025, while Asia-Pacific is expected to post the fastest growth.

Why it matters: - PD-L1 and PIK3CA testing helps doctors match cancer patients to targeted therapies and immunotherapy. - Rising cancer incidence is expanding demand for biomarker-driven diagnostics. - The market’s projected 15.2% CAGR through 2030 signals continued investment in precision oncology tools.

What happened: - The Business Research Company released its PD-L1 And PIK3CA Testing Global Market Report 2026, covering market size, trends and forecasts for 2026-2035. - The report values the market at $1.67 billion in 2025 and $1.93 billion in 2026. - The company projects the market will reach $3.4 billion by 2030. - The report forecasts a 15.5% CAGR in 2026 and a 15.2% CAGR through the 2030 outlook period.

The details: - PD-L1 testing measures programmed death-ligand 1 expression on tumor cells to help predict response to immunotherapy. - PIK3CA testing identifies mutations in the PIK3CA gene to assess eligibility for therapies targeting the PI3K signaling pathway. - Market growth has been supported by assay development, broader use in clinical trials, rising cancer rates, improved molecular diagnostics and higher awareness of personalized medicine. - Future growth drivers include AI in biomarker detection, wider use of liquid biopsy methods, strategic partnerships between diagnostics and pharmaceutical firms, and regulatory approvals for next-generation assays. - The report highlights targeted biomarker testing, AI-based mutation analysis, high-throughput genomic screening and closer alignment with drug development pipelines as key trends. - North America held the largest market share in 2025. - Asia-Pacific is expected to be the fastest-growing region during the forecast period. - The regional analysis also covers South East Asia, Western Europe, Eastern Europe, South America, the Middle East and Africa. - The report cites the American Cancer Society, which projected in September 2024 that global cancer cases among men will rise 84% by 2029, from 10.3 million in 2022 to 19 million. - The 2026 report edition includes market attractiveness scoring, TAM analysis, company scoring matrix graphics and tables, Excel-based forecasting dashboards, market hotspots infographics, key technology analysis and updated graphics. - The report offers a free sample and a full version through The Business Research Company. More information - The full report is available here. Read the report

Between the lines: - The forecast points to a diagnostics market increasingly tied to oncology drug development, not just routine testing. - AI and liquid biopsy are likely to reshape how quickly and broadly biomarker testing can be deployed. - Regional leadership appears to be shifting from a mature North American base toward faster growth in Asia-Pacific.

What's next: - Diagnostics firms and drugmakers are likely to pursue more partnerships around companion diagnostics and precision oncology workflows. - Regulatory progress on newer assays could accelerate adoption over the forecast period. - Market competition may intensify as liquid biopsy and AI-enabled tools move from emerging use cases into broader clinical adoption.